ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

UnitedHealth Group (NYSE: UNH) has spent a significant amount of time in the sick bay for the first half of 2025, but it’s ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

After years of collecting consumer DNA, genetic testing companies are monetizing the data. But who should profit — the ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults ...

The Food and Drug Administration on Monday granted marketing approval to GlaxoSmithKline for Priorix, a vaccine to prevent measles, mumps and rubella in individuals a year or older.

As per the deal, GlaxoSmithKline will pay the vaccine maker up to $1.2 billion more if certain milestones are arrived at in Affinivax's impending clinical trials for a new pneumococcal vaccine.

GlaxoSmithKline renames as GSK GlaxoSmithKline has renamed its company to simply GSK.

GlaxoSmithKline has been called GSK for years — but the pharma company officially made the move to simplify the name this week. GlaxoSmithKline is now officially just GSK, the company announced Monday ...